Aaron E. Katz, MD, FACS

home / authors / aaron-e-katz-md-facs

Articles

Dr. Katz on Redefining Risk Stratification in Prostate Cancer

Dr. Katz on Redefining Risk Stratification in Prostate Cancer

Aaron E. Katz, MD, FACS
July 9th 2020

Aaron E. Katz, MD, FACS, discusses redefining risk stratification for men with prostate cancer.

Read More

Dr. Katz on the Oncotype DX GPS Assay in Prostate Cancer

Dr. Katz on the Oncotype DX GPS Assay in Prostate Cancer

Aaron E. Katz, MD, FACS
June 18th 2020

Aaron E. Katz, MD, FACS, discusses the Oncotype DX Genomic Prostate Score assay in patients with prostate cancer.

Read More

Dr. Katz on Redefining Risk Assessment in Prostate Cancer With 17-Gene Oncotype DX GPS

Dr. Katz on Redefining Risk Assessment in Prostate Cancer With 17-Gene Oncotype DX GPS

Aaron E. Katz, MD, FACS
June 3rd 2020

Aaron E. Katz, MD, FACS, discusses re-classifying low-risk prostate scores with the 17-gene Oncotype DX Genomic Prostate Score.

Read More

Dr. Katz on Determining Low-Risk Disease in Prostate Cancer

Dr. Katz on Determining Low-Risk Disease in Prostate Cancer

Aaron E. Katz, MD, FACS
June 2nd 2020

Aaron E. Katz, MD, FACS, discusses strategies for determining low-risk prostate cancer.

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data